Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim

NCT01311336 is registered in ClinicalTrials.gov with University of Vermont as lead sponsor.

NCT NCT01311336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01311336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim
Lead sponsor
University of Vermont
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2011
Completion date
June 30, 2013
Enrollment
55 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pegfilgrastim-induced back and leg pain